2Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drogclopidogrel [ J ]. Arterioscler Thromb Vasc Biol, 1999,19 ( 8 ) : 2007 -2011.
3Savi P, Herbert JM. Clopidogrel and ticlopidine : P2Y12 adeno- sine diphophate receptor antagonists for the prevention of atherothrombosis [ J ]. Semin Thrurnb Hemost, 2005,31 ( 2 ) : 174-183.
6Collaborative overview of randomised trials of antiplateletherapy I: prevention of death, myocardial infarction, and stroke by prolonyed antiplatelet therapy in various cateyories of patients. Antiplatelet Trialists Collaboration [J ]. BMJ, 1994, 308 ( 6943 ) : 1540.
7Geiger J, Brich J, Honig - Liedl P, et al. Specific impairment of human platelet P2Y(AC)ADP receptor-mediated signaling by the antiplatelet drugclopidogrel[J]. Arterioscler Thromb Vasc Biol, 1999, 19(8) :2007 - 2011.
8Savi P, Herbert JM. Clopidogrel and tidopidine: P2Y12 adenosine diphosphate receplor antagonists for the prevention of atherothrombois [J]. Semin Thrumb Hemost, 2005, 31(2) : 174 - 183.
9Collaborative overview of randomised trials of antiplatelet therapy -I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration [ J ]. BMJ, 1994, 308 (6921): 1540.
10Savi P, Herbert JM. Clopidogrel and tielopidine : P2Y12 adenosine diphosphate-receptor antagonists for the prevention of athero- thrombosis[J]. Semin Thromb Hemost,2005,31(2) :174-183.
